Halozyme Therapeutics Inc. has completed its previously announced acquisition of Elektrofi Inc., a biopharmaceutical company with a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.

Halozyme has acquired Elektrofi for an upfront payment of $750 million, subject to customary purchase price adjustments, and up to three $50 million milestone payments contingent on three separate product regulatory approvals, for a total consideration of up to $900 million at approvals.

The acquisition of Elektrofi is a strategic milestone in Halozyme’s mission to expand its drug delivery technology offerings to biopharma companies.

“With the addition of the Hypercon ultra-high concentration microparticle formulation technology, we will be able to offer partners a diverse portfolio of drug delivery solutions,” said Dr. Helen Torley, President and Chief Executive of Halozyme. “Most importantly, this acquisition reinforces our mission to transform how vital medicines are delivered, ensuring treatments fit seamlessly into a patient’s life, rather than patients having to shape their lives around treatment.”

“We are excited to welcome the talented Elektrofi team to Halozyme,” Torley added. “We look forward to supporting their continued innovation and execution as we now advance the two programs into the clinic before year end 2026, a key step toward unlocking the potential of the Hypercon platform and delivering long-term value to our partners and shareholders.”

Other Pharma Industry Acquisitions

Check out Contract Pharma’s Pharmaceutical Industry Mergers & Acquisitions Roundup.